natgillin/translations-raw huggingface dataset:
Fluticasone furoate or vilanterol has no or negligible influence on the ability to drive and use machines. 
Flutikazonfuroat ili vilanterol ne utječu ili zanemarivo utječu na sposobnost upravljanja vozilima i rada sa strojevima.
Take one long, steady, deep breath in. 
Udahnite jednom dugo i duboko.
In the asthma clinical development program a total of 7,034 patients were included in an integrated assessment of adverse reactions. 
U kliničkom razvojnom programu obuhvaćeno je ukupno 7034 bolesnika s astmom radi objedinjene procjene nuspojava.
Both studies had a 4 week run-in period during which all subjects received open-label salmeterol/FP 50/250 twice daily to standardise COPD pharmacotherapy and stabilise disease prior to randomisation to blinded study medication for 52 weeks. 
Oba su ispitivanja imala razdoblje prilagodbe od 4 tjedna, tijekom kojega su svi ispitanici otvoreno primali salmeterol/flutikazonpropionat od 50/250 mikrograma dvaput na dan kako bi se standardizirala farmakoterapija za KOPB i stabilizirala bolest prije randomizacije za primjenu lijeka u slijepom ispitivanju u trajanju od 52 tjedna.
Fluticasone furoate was not genotoxic in a standard battery of studies and was not carcinogenic in lifetime inhalation studies in rats or mice at exposures similar to those at the maximum recommended human dose, based on AUC. 
Flutikazonfuroat se nije pokazao genotoksičnim u standardnom skupu ispitivanja niti kancerogenim u ispitivanjima cjeloživotne inhalacije na štakorima ili miševima pri razinama izloženosti sličnima onima kod najveće preporučene doze u ljudi, utvrđene na temelju AUC-a.
Fluticasone furoate and vilanterol are both substrates of P-glycoprotein (P-gp). 
Flutikazonfuroat i vilanterol su oboje supstrati za P-glikoprotein (P-gp).
Elderly patients (> 65 years old) 
Stariji bolesnici (> 65 godina)
This helps to open the airways and makes it easier for air to get in and out of the lungs. 
Na taj se način otvaraju dišni putovi te se olakšava ulazak zraka u pluća i izlazak zraka iz pluća.
Prescribers should be aware that in patients with asthma, fluticasone furoate (FF) 100 micrograms once daily is approximately equivalent to fluticasone propionate (FP) 250 micrograms twice daily, while FF 200 micrograms once daily is approximately equivalent to FP 500 micrograms twice daily. 
Liječnici koji propisuju lijek moraju znati da je u bolesnika s astmom doza flutikazonfuroata (FF) od 100 mikrograma jedanput na dan približno ekvivalentna dozi flutikazonpropionata (FP) od 250 mikrograma dvaput na dan, dok je doza flutikazonfuroata od 200 mikrograma jedanput na dan približno ekvivalentna dozi flutikazonpropionata od 500 mikrograma dvaput na dan.
Both fluticasone furoate and vilanterol have a low association with red blood cells. 
I flutikazonfuroat i vilanterol se u maloj mjeri vezuju za crvene krvne stanice.
Don't open the inhaler until you are ready to inhale a dose of medicine. 
Nemojte otvarati inhalator dok ne budete spremni inhalirati dozu lijeka.
Don't use this medicine if you are pregnant unless your doctor tells you that you can. 
Nemojte primijeniti ovaj lijek ako ste trudni, osim ako
Fluticasone furoate and vilanterol represent two classes of medications (a synthetic corticosteroid and a selective, long-acting beta2-receptor agonist). 
Flutikazonfuroat i vilanterol predstavljaju dvije skupine lijekova (sintetički kortikosteroid i dugodjelujući selektivni agonist beta2-receptora).
Relvar Ellipta should not be used in conjunction with other long-acting beta2-adrenergic agonists or medicinal products containing longacting beta2-adrenergic agonists. 
Relvar Ellipta se ne smije koristiti u kombinaciji s drugim dugodjelujućim agonistima beta2-adrenergičkih receptora niti lijekovima koji sadrže dugodjelujuće beta2-adrenergičke agoniste.
Symptoms come and go and include shortness of breath, wheezing, chest tightness and cough. 
Simptomi dolaze i prolaze, a uključuju nedostatak zraka, piskanje pri disanju, stezanje u prsima i kašalj.
Elderly patients (>65 years) 
Stariji bolesnici (>65 godina)
Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1<70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy. 
Relvar Ellipta je indiciran za simptomatsko liječenje odraslih bolesnika s KOPB-om koji imaju FEV1 < 70% predviđene normalne vrijednosti (nakon primjene bronhodilatatora) i s egzacerbacijama bolesti unatoč redovitom liječenju bronhodilatatorima.
Adjusted mean change from baseline in trough FEV1 was also evaluated as a secondary endpoint. 
Prilagođena srednja vrijednost promjene najniže vrijednosti FEV1 od početne također je ocijenjena kao sekundarna mjera ishoda.
Pharmacotherapeutic group: Drugs for obstructive airways diseases, adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics ATC code: R03AK10. 
Farmakoterapijska skupina: Lijekovi za liječenje opstruktivnih bolesti dišnih puteva, adrenergici u kombinaciji s kortikosteroidima ili drugim lijekovima, osim antikolinergika, ATK oznaka: R03AK10.
The use of concurrent inhaled long-acting bronchodilators (beta2-agonist and anticholinergic), ipratropium/salbutamol combination products, oral beta2-agonists, and theophylline preparations were not allowed during the treatment period. 
Istodobna primjena dugodjelujućih inhalacijskih bronhodilatatora (beta2-agonista i antikolinergika), lijekova s kombinacijom ipratropija/salbutamola, peroralnih beta2-agonista i teofilina nije bila dopuštena tijekom liječenja.
Patients usually experience an improvement in lung function within 16-17 minutes of inhaling Relvar Ellipta. 
Bolesnici obično osjete poboljšanje plućne funkcije unutar 16-17 minuta nakon inhaliranja lijeka Relvar Ellipta.
The European Medicines Agency has waived the obligation to submit the results of studies with Relvar Ellipta in all subsets of the paediatric population in COPD (see section 4.2 for information on paediatric use). 
Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka Relvar Ellipta u svim podskupinama pedijatrijske populacije u KOPB-u (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
Given this low oral bioavailability, systemic exposure for fluticasone furoate and vilanterol following inhaled administration is primarily due to absorption of the inhaled portion of the dose delivered to the lung. 
S obzirom na tu nisku bioraspoloživost, sistemska izloženost flutikazonfuroatu i vilanterolu nakon inhalacijske primjene prvenstveno je posljedica apsorpcije inhaliranog dijela doze lijeka koji se isporučuje u pluća.
The effective half-life for accumulation of vilanterol, as determined from inhalation administration of repeat doses of vilanterol 25 micrograms, is 16.0 hours in subjects with asthma and 21.3 hours in subjects with COPD. 
Efektivni poluvijek akumulacije vilanterola, utvrđen na temelju inhalacijske primjene ponovljenih doza vilanterola od 25 mikrograma, iznosi 16,0 sati u ispitanika s astmom odnosno 21,3 sata u ispitanika s KOPB-om.
Following oral administration, fluticasone furoate was eliminated in humans mainly by metabolism with metabolites being excreted almost exclusively in faeces, with <1% of the recovered radioactive dose eliminated in the urine. 
Nakon peroralne primjene, flutikazonfuroat se u ljudi uglavnom eliminirao metabolizmom, a metaboliti su se izlučivali gotovo isključivo u feces, pri čemu se <1% pronađene radioaktivne doze izlučilo u mokraću.
Asthma is a serious, long term lung disease where the muscles surrounding the smaller airways become tight (bronchoconstriction) and swollen and irritated (inflammation). 
Astma je ozbiljna i dugotrajna plućna bolest u kojoj dolazi do stezanja mišića koji okružuju manje dišne puteve (bronhokonstrikcija) te do oticanja i nadraženosti (upala) malih dišnih puteva.
The safety and efficacy of fluticasone furoate/vilanterol in children under the age of 12 years has not yet been established. 
Sigurnost i djelotvornost flutikazonfuroata/vilanterola u djece mlađe od 12 godina nisu još ustanovljene.
Subjects used salbutamol on an as-needed basis throughout the studies. 
Ispitanici su po potrebi uzimali salbutamol tijekom čitavog trajanja obaju ispitivanja.
The adjusted mean treatment difference of 22 mL (95% CI: -18, 63mL) between the groups was not statistically significant (p=0.282). 
Prilagođena srednja vrijednost terapijskih razlika od 22 ml (95% CI: -18, 63 ml) između skupina nije bila statistički značajna (p=0,282).
Relvar Ellipta has been shown to reduce flare-ups and symptoms of asthma. 
Pokazalo se da Relvar Ellipta smanjuje razbuktavanje i simptome astme.
The most commonly reported adverse reactions with fluticasone furoate and vilanterol were headache and nasopharyngitis. 
Najčešće prijavljivane nuspojave kod primjene flutikazonfuroata i vilanterola bile su glavobolja i nazofaringitis.
Just follow these step-by-step instructions. 
Samo slijedite ove upute koje opisuju njegovu uporabu korak po korak.
Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g. eosinophils, macrophages, lymphocytes) and mediators (e.g. cytokines and chemokines involved in inflammation). 
Pokazalo se da kortikosteroidi imaju širok spektar djelovanja na više tipovastanica (npr. na eozinofile, makrofage, limfocite) i posrednika (npr. na citokine i kemokine koji sudjeluju u upali).
The 184/22 micrograms strength is used to treat asthma in adults and adolescents aged 12 years and older. 
Doza od 184/22 mikrograma koristi se za liječenje astme u odraslih osoba i adolescenata u dobi 12 i više godina.
During clinical studies, pneumonia and fractures were more frequently commonly observed in patients with COPD. 
Pneumonija i frakture su tijekom kliničkih ispitivanja češće zabilježene u bolesnika s KOPB-om.
• heart beating faster (tachycardia) 
• brži otkucaji srca (tahikardija)
Caution should be exercised when dosing patients with hepatic impairment who may be more at risk of systemic adverse reactions associated with corticosteroids. 
Potreban je oprez pri doziranju u bolesnika s oštećenjem jetrene funkcije koji bi mogli biti izloženi povećanom riziku od sistemskih nuspojava povezanih s kortikosteroidima.
Influenza 
• gripa
The pharmacologic effects of beta2-adrenoceptor agonist active substance, including vilanterol trifenatate, are at least in part attributable to stimulation of intracellular adenylate cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). 
Farmakološki učinci agonista beta2-adrenoreceptora, uključujući vilanteroltrifenatat, barem se djelomično mogu pripisati stimulaciji unutarstanične adenilat ciklaze, enzima koji katalizira pretvorbu adenozin trifosfata (ATP) u 3',5'-ciklički adenozin monofosfat (ciklički AMP).
Studies versus salmeterol/fluticasone propionate combinations 
Ispitivanja u odnosu na kombinacije salmeterola/flutikazonpropionata
The step-by-step instructions shown below for the 30-dose Ellipta inhaler (30 day supply) also apply to the 14-dose Ellipta inhaler (14 day supply). 
Upute koje korak po korak opisuju uporabu Ellipta inhalatora s 30 doza (terapija za 30 dana), prikazane u nastavku, odnose se i na Ellipta inhalator s 14 doza (terapija za 14 dana).
Subjects had moderate COPD (mean percent post-bronchodilator screening FEV1 of 60% [SD = 6%]), and a history of, or an increased risk of cardiovascular disease. 
Ispitanici su imali umjereni KOPB (srednji postotak FEV1 nakon primjene bronhodilatatora pri probiru iznosio je 60% [SD = 6%]) te kardiovaskularnu bolest u anamnezi ili povećan rizik od kardiovaskularne bolesti.
Use Relvar Ellipta at the same time each day as it is effective over 24 hours It is very important that you use this medicine every day, as instructed by your doctor. 
Primjenjujte Relvar Ellipta svakoga dana u isto vrijeme jer je on učinkovit tijekom 24 sata
Increasing use of short-acting bronchodilators to relieve symptoms indicates deterioration of control and patients should be reviewed by a physician. 
Pojačano korištenje kratkodjelujućih bronhodilatatora za ublažavanje simptoma ukazuje na pogoršanje tj. neadekvatnu kontrolu bolesti te se preporučuje kontrola liječnika.
Fluticasone furoate and vilanterol are both rapidly cleared by extensive first pass metabolism mediated by the liver enzyme CYP3A4. 
I flutikazonfuroat i vilanterol brzo se uklanjaju ekstenzivnim metabolizmom prvog prolaska u kojem posreduje jetreni enzim CYP3A4.
All subjects had to have been on a stable dose of an ICS for at least 4 weeks prior to visit 1 (screening visit) and the use of LABAs was not permitted within 4 weeks of visit 1. 
Svi su ispitanici prethodno morali primati stabilnu dozu inhalacijskog kortikosteroida najmanje 4 tjedna prije 1. posjeta (posjeta probira), a primjena dugodjelujućih beta2-agonista nije bila dopuštena unutar 4 tjedna od 1. posjeta.
Consistent with findings for other beta2 agonists, in lifetime inhalation studies vilanterol trifenatate caused proliferative effects in the female rat and mouse reproductive tract and rat pituitary gland. 
Sukladno nalazima za druge beta2-agoniste, vilanteroltrifenatat je u ispitivanjima cjeloživotne inhalacije imao proliferativne učinke na reproduktivni sustav u ženki štakora i miša te na hipofizu u štakora.
4.4 Special warnings and precautions for use 
4.4 Posebna upozorenja i mjere opreza pri uporabi Pogoršanje bolesti
The apparent plasma elimination half-life of vilanterol following single inhaled administration of fluticasone furoate/vilanterol was, on average, 2.5 hours. 
Prividni poluvijek eliminacije vilanterola u plazmi nakon jedne inhalacijske primjene flutikazonfuroata/vilanterola u prosjeku je iznosio 2,5 sata.
Throw this desiccant sachet away - don't open, eat or inhale it. 
Bacite tu vrećicu sa sredstvom za sušenje- nemojte je otvarati, jesti niti udisati.
FF/VI 184/22 Once Daily vs FF 184 Once Daily 
FF/VI 184/22 jedanput na dan naspram FF 184 jedanput na dan
FF/VI 92/22 Once Daily vs placebo Once Daily Change from Baseline in Trough FEV1 Last Observation Carried Forward (LOCF) Treatment difference P value (95% CI) 
FF/VI 92/22 jedanput na dan naspram placebo jedanput na dan Promjena početne najniže vrijednosti FEV1 u odnosu na zadnje opažanje preneseno nadalje (LOCF) Terapijska razlika P vrijednost (95% CI)
These synergistic interactions are reflected in enhanced anti-inflammatory activity, which has been demonstrated in vitro and in vivo in a range of inflammatory cells relevant to the pathophysiology of both asthma and COPD. 
Sinergijski učinak ovih lijekova dovodi do pojačanog protuupalnog djelovanju, što je dokazano in vitro i in vivo na nizu upalnih stanica bitnih za patofiziologiju i astme i KOPB-a.
Prior to run-in, subjects discontinued use of previous COPD medications except short-acting bronchodilators. 
Prije razdoblja prilagodbe svi su ispitanici prestali koristiti prethodne lijekove za liječenje KOPB-a, osim kratkodjelujućih bronhodilatatora.
• Rinse your mouth with water after you have used the inhaler, do not swallow. 
• Isperite usta vodom nakon korištenja inhalatora, nemojte je progutati.
The following convention has been used for the classification of frequencies: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000). 
Za određivanje učestalosti korištene su sljedeće kategorije: vrlo često (≥1/10); često (≥1/100 i <1/10); manje često (≥1/1000 i
If the dose counter does not count down as you hear the ‘click', the inhaler will not deliver medicine. 
Ako se broj na brojaču doza ne smanji za 1 kada čujete ''klik'', inhalator neće isporučiti lijek.
On average, vilanterol Cmax is predicted to be 220 to 287% higher and AUC(0-24) comparable for those subjects from an Asian heritage compared with subjects from other racial groups. 
U prosjeku se predviđa da je Cmax vilanterola 220 do 287% viši u ispitanika azijskog podrijetla nego u ispitanika iz ostalih rasnih skupina, dok im je AUC(0-24) usporediv.
Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. 
Povećane razine cikličkog AMP-a uzrokuju opuštanje glatkih mišića bronha te inhibiraju otpuštanje medijatora iz stanica, osobito iz mastocita, a koji sudjeluju u reakcijama neposredne preosjetljivosti.
Cardioselective beta-blockade should only be considered for profound vilanterol overdose effects that are clinically concerning and unresponsive to supportive measures. 
Primjenu kardioselektivnih beta-blokatora treba razmotriti samo kod teških klinički manifestinih predoziranja vilanterolom koji ne reagiraju na potporne mjere liječenja.
The bronchoprotective effect of fluticasone furoate/vilanterol 92/22 micrograms on the early and late asthmatic response to inhaled allergen was evaluated in a repeat dose, placebo-controlled four-way crossover study (HZA113126) in patients with mild asthma. 
Bronhoprotektivni učinak flutikazonfuroata/vilanterola od 92/22 mikrograma na rani i kasni astmatički odgovor na inhalirani alergen ocijenjen je u placebom kontroliranom, četverosmjernom križnom ispitivanju ponovljenih doza (HZA113126) u bolesnika s blagom astmom.
Although there were more fractures in the Relvar Ellipta groups compared with the vilanterol 22 micrograms group, fractures typically associated with corticosteroid use (e.g., spinal compression/thoracolumbar vertebral fractures, hip and acetabular fractures) occurred in <1% of the Relvar Ellipta and vilanterol treatment arms. 
Premda je u skupinama koje su primale Relvar Ellipta fraktura bilo više nego u skupinama koje su primale vilanterol od 22 mikrograma, frakture koje se u pravilu povezuju s primjenom kortikosteroida (npr. kompresivni prijelomi torako-lumbalnih kralježaka, frakture kuka i zglobne čašice) zabilježene su u <1% ispitanika i u skupinama koje su primale Relvar Ellipta i u onima koje su primale vilanterol.
The effects of haemodialysis have not been studied. 
Učinci hemodijalize nisu ispitivani.
The pharmacokinetics of fluticasone furoate/vilanterol in patients less than 12 years of age has not been studied. 
Nije ispitivana farmakokinetika flutikazonfuroata/vilanterola u bolesnika mlađih od 12 godina.
Put the mouthpiece between your lips and close your lips firmly around it. 
Stavite nastavak za usta među usne i čvrsto ga obujmite usnama.
Rinse your mouth with water after you have used the inhaler, do not swallow. 
Isperite usta vodom nakon korištenja inhalatora, nemojte je progutati.
The results of both studies showed that treatment with fluticasone furoate/vilanterol 92/22 micrograms once daily resulted in a lower annual rate of moderate/severe COPD exacerbations compared with vilanterol (Table 2). 
Rezultati obaju ispitivanja pokazali su da je liječenje flutikazonfuroatom/vilanterolom od 92/22 mikrograma jedanput na dan rezultiralo nižom godišnjom stopom umjerenih/teških egzacerbacija KOPB-a u odnosu na vilanterol (Tablica 2).
In peripheral blood mononuclear cells from subjects with COPD, a larger anti-inflammatory effect was seen in the presence of the combination of fluticasone furoate/vilanterol compared with fluticasone furoate alone at concentrations achieved with clinical doses. 
mononuklearnim stanicama periferne krvi ispitanika s KOPB-om primijećen je jači protuupalni učinak u prisutnosti kombinacije flutikazonfuroat/vilanterol u usporedbi s prisutnošću samo flutikazonfuroata pri koncentracijama koje se postižu primjenom kliničkh doza.
PHARMACEUTICAL FORM Inhalation powder, pre-dispensed (Inhalation powder). 
OBLIK Prašak inhalata, dozirani (Prašak inhalata).
Allergen challenge study 
Provokacijsko ispitivanje s alergenima
• If the dose counter does not count down as you hear the “click”, the inhaler will not deliver medicine. 
• Ako se broj na brojaču doza ne smanji za 1 kada čujete ''klik'', inhalator neće isporučiti lijek.
Driving and using machines This medicine is unlikely to affect your ability to drive or use machines. 
Nije vjerojatno da bi ovaj lijek mogao utjecati na Vašu sposobnost upravljanja vozilima ili rada sa strojevima.
Slide the cover upwards as far as it will go to cover the mouthpiece. 
Povucite poklopac prema gore koliko ide kako biste prekrili nastavak za usta.
However, the patient should be informed that regular daily usage is necessary to maintain control of asthma symptoms and that use should be continued even when asymptomatic. 
Međutim, bolesniku treba napomenuti da je za održavanje simptoma astme pod kontrolom potrebno redovito uzimati lijek svakoga dana te da s primjenom treba nastaviti čak i ako nema simptoma.
The MAH shall perform the required Pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP. 
• Plan upravljanja rizikom (RMP) Nositelj odobrenja obavljat će zadane farmakovigilancijske aktivnosti i intervencije, detaljno objašnjene u dogovorenom Planu upravljanja rizikom (RMP), koji se nalazi u Modulu 1.8.2
In two replicate 12 month studies in a total of 3,255 patients with COPD the incidence of bone fractures overall was low in all treatment groups, with a higher incidence in all Relvar Ellipta groups (2%) compared with the vilanterol 22 micrograms group (<1%). 
U dva 12-mjesečna replikacijska ispitivanja u kojima je sudjelovalo ukupno 3255 bolesnika s KOPB-om, ukupna incidencija fraktura kostiju bila je niska u svim liječenim skupinama, s time da je incidencija bila viša u svim skupinama u kojima su bolesnici primali Relvar Ellipta (2%) nego u skupinama koje su primale vilanterol od 22 mikrograma (<1%).
A clinical pharmacology study of fluticasone furoate/vilanterol showed that severe renal impairment (creatinine clearance <30mL/min) did not result in significantly greater exposure to fluticasone furoate or vilanterol or more marked corticosteroid or beta2-agonist systemic effects compared with healthy subjects. 
Kliničko farmakološko ispitivanje flutikazonfuroata/vilanterola pokazalo je da teško oštećenje bubrežne funkcije (klirens kreatinina <30 ml/min) nije rezultiralo značajno većom izloženošću flutikazonfuroatu ili vilanterolu niti izraženijim sistemskim učincima kortikosteroida ili beta2-agonista u odnosu na zdrave ispitanike.
There are no or limited data from the use of fluticasone furoate and vilanterol trifenatate in pregnant women. 
Nema podataka ili postoje samo ograničeni podaci o primjeni flutikazonfuroata i vilanteroltrifenatata u trudnica.
The final decision on evening or morning dosing should be left to the discretion of the physician. 
Konačnu odluku o tome hoće li se lijek uzimati uvečer ili ujutro donosi liječnik.
There is no specific treatment for an overdose with fluticasone furoate/vilanterol. 
Nema posebne terapije za predoziranje flutikazonfuroatom/vilanterolom.
FF/VI 92/22 Once Daily vs FF 92 Once Daily 
FF/VI 92/22 jedanput na dan naspram FF 92 jedanput na dan
If you feel you are getting breathless or wheezy more often than normal, or if you are using your quickacting inhaler more than usual, see your doctor. 
Ako ostajete bez zraka, primjećujete piskanje pri disanju ili primjenjujete brzodjelujući inhalacijski lijek češće nego obično, posjetite svog liječnika.
The absolute bioavailability for fluticasone furoate and vilanterol when administered by inhalation as fluticasone furoate/vilanterol was on average 15.2% and 27.3%, respectively. 
Apsolutna bioraspoloživost flutikazonfuroata i vilanterola primijenjenih inhalacijom u obliku flutikazonfuroata/vilanterola u prosjeku je iznosila 15,2% odnosno 27,3%.
Serial FEV1 measurements were compared with pre-allergen challenge values taken after saline inhalation (baseline). 
Serijska mjerenja vrijednosti FEV1 uspoređena su s vrijednostima prije provokacije alergenom izmjerenima nakon inhalacije fiziološke otopine (početna vrijednost).